Blood News and Research

RSS

Increase in levels of P450 protein creates EET molecules that lower blood pressure

If you are one of the millions of Americans with high blood pressure, more help is on the way. That's because a new research study published in the October 2010 print issue of The FASEB Journal shows that a protein, called P450, metabolizes arachidonic acid in our blood vessel walls to create a tiny molecule with a big name-epoxyeicosatrienoic acid (EET)-which in mice, turns off genes responsible for vascular inflammation and ultimately relaxes blood vessels to lower blood pressure. This protein and genes are also present in humans.

1 Oct 2010

Study examines link between insufficient sleep and blood pressure among pregnant women

A study in the Oct. 1 issue of the journal Sleep found that getting too little or too much sleep in early pregnancy is associated with elevated blood pressure in the third trimester. The study suggests that improving prenatal sleep hygiene may provide important health benefits.

1 Oct 2010

Center for Excellence in Sickle Cell Disease established by Vanderbilt and Meharry

A Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease has been established by Vanderbilt University Medical Center and Meharry Medical College. The Center will seek to bring high quality care to people with sickle cell disease (SCD) that is seamless and lifelong.

1 Oct 2010

Report finds development of multiple myeloma is tied to 'hypomethylation'

DNA methylation - a modification of DNA linked to gene regulation - is altered with increasing severity in a blood cancer called multiple myeloma, according to a study by Mayo Clinic and the Translational Genomics Research Institute (TGen).

1 Oct 2010

Researchers study potential of menstrual blood-derived stem cells for stroke therapy

The potential for stem cells derived from menstrual blood to benefit stroke sufferers will be jointly investigated by researchers at the University of South Florida, Cryo-Cell International, Inc., a global stem cell company based in Oldsmar, FL, and Saneron CCEL Therapeutics, Inc. a Tampa-based biotechnology company.

1 Oct 2010

UAB Comprehensive Cancer Center wins $11.5M grant for pancreatic cancer research

The University of Alabama at Birmingham Comprehensive Cancer Center, in collaboration with the University of Minnesota, has won an $11.5 million grant from the National Cancer Institute to explore groundbreaking pancreatic cancer research, prevention and treatment.

1 Oct 2010

Researchers study gene interactions for personalized drug prescriptions

The University of Alaska Fairbanks will study how the genetics and diet of Yup'ik Eskimos affect the blood-thinning properties of a common drug used by heart and stroke patients.

1 Oct 2010

NIH funds $1.5M for research into prediction of stroke risk in pediatric patients with sickle cell disease

A researcher from the biomedical engineering department operated by Georgia Tech and Emory University has received a $1.5 million NIH Director's New Innovator Award to support a project aimed at reducing the incidence of stroke in children with sickle cell disease. Manu Platt, an assistant professor in the Wallace H. Coulter Department of Biomedical Engineering, will use the National Institutes of Health (NIH) funding to develop models for identifying which children with the disease are at risk for stroke.

1 Oct 2010

Antiretroviral therapy does not reduce risk of HIV transmission

For married couples in which one partner is HIV-positive and the other is HIV-negative, antiretroviral therapy (ART) does not reduce the risk of transmitting HIV to the uninfected partner, according to a study from China in the October issue of JAIDS: Journal of Acquired Immune Deficiency Syndromes.

1 Oct 2010

Researchers discover key leukemia defense mechanism

Virginia Commonwealth University Massey Cancer Center researcher Steven Grant, M.D., and a team of VCU Massey researchers have uncovered the mechanism by which leukemia cells trigger a protective response when exposed to a class of cancer-killing agents known as histone deacetylase inhibitors (HDACIs).

1 Oct 2010

South Asian ethnicity is a risk factor for cardiovascular events after renal transplantation

Ethnicity is a contributing risk factor of cardiovascular problems in kidney recipients of South Asian origin post-transplant, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

1 Oct 2010

Personalized cancer drug delivery could soon be a reality

Imagine the day a machine can draw your blood, screen it for genetic mutations and chemical variations that can cause cancer, and pop out a drug tailor-made for your DNA.

1 Oct 2010

APhA urges consumers to discuss proper medication usage with pharmacists

In honor of American Pharmacists Month, the American Pharmacists Association (APhA) encourages consumers to hold an open dialogue with their pharmacists about a growing problem in the United States, the proper usage of and adherence to medications.

1 Oct 2010

Neurologic Clinics journal publishes latest advances in neurologic disorders

The latest advances in treating neurologic disorders such as stroke, headache, Parkinson's disease, epilepsy and sleep disorders are detailed in a special issue of the journal Neurologic Clinics.

1 Oct 2010

NIH awards Polymedix $986,000 to develop defensin mimetic antimicrobial compounds for oral candidiasis

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a Phase 2 grant in the amount of $986,000 from the National Institute of Health (NIH) to support the development of defensin mimetic antimicrobial compounds for the treatment of oral candidiasis. This grant will fund this research project through August 31, 2012. This award represents the 14th grant or research contract received to date by PolyMedix.

30 Sep 2010

'Intraluminal protection' IV needleless connector more effective in preventing CLABSIs: Study

A lengthy study performed at Methodist Extended Care Hospital resulted in the elimination of potentially deadly infections. The study findings were reported in a scientific poster presentation at the recent annual meeting of the Association for Vascular Access (AVA), a leading national organization focusing on patient safety and best nursing practices.

30 Sep 2010

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.

30 Sep 2010

Healthy and Essential develops World's first limited edition fish oil SuperFood

Blackpool Football Club surprised many last season and they continue to defy the so called experts with some excellent performances so far in their debut Premier League season. In tribute of Blackpool's amazing achievements, a Lancashire based Company called Healthy and Essential Ltd has developed the World's first limited edition fish oil SuperFood called 'Tangerine Dream'.

30 Sep 2010

Concentric Medical commences TREVO Study of Stentriever technology in ischemic stroke patients

Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced the start of the TREVO Study. The first patients were enrolled and successfully treated at the Hospital Clinic de Barcelona by the Neuroradiology team of Drs. Juan Macho and Jordi Blasco.

30 Sep 2010

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note that its partner, sanofi-aventis, has today announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered by Zealand Pharma, in combination with basal insulin.

30 Sep 2010

Blood News and Research

Increase in levels of P450 protein creates EET molecules that lower blood pressure

Study examines link between insufficient sleep and blood pressure among pregnant women

Center for Excellence in Sickle Cell Disease established by Vanderbilt and Meharry

Report finds development of multiple myeloma is tied to 'hypomethylation'

Researchers study potential of menstrual blood-derived stem cells for stroke therapy

UAB Comprehensive Cancer Center wins $11.5M grant for pancreatic cancer research

Researchers study gene interactions for personalized drug prescriptions

NIH funds $1.5M for research into prediction of stroke risk in pediatric patients with sickle cell disease

Antiretroviral therapy does not reduce risk of HIV transmission

Researchers discover key leukemia defense mechanism

South Asian ethnicity is a risk factor for cardiovascular events after renal transplantation

Personalized cancer drug delivery could soon be a reality

APhA urges consumers to discuss proper medication usage with pharmacists

Neurologic Clinics journal publishes latest advances in neurologic disorders

NIH awards Polymedix $986,000 to develop defensin mimetic antimicrobial compounds for oral candidiasis

'Intraluminal protection' IV needleless connector more effective in preventing CLABSIs: Study

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Healthy and Essential develops World's first limited edition fish oil SuperFood

Concentric Medical commences TREVO Study of Stentriever technology in ischemic stroke patients

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News